XBIT - XBiotech Inc Stock Price, Fair Value and News

8.46USD-0.13 (-1.51%)Delayed as of 16 May 2024, 02:02 pm ET

Market Summary

USD8.46-0.13

Delayedas of 16 May 2024, 02:02 pm

-1.51%

XBIT Stock Price

View Fullscreen

XBIT RSI Chart

XBIT Valuation

Market Cap

261.6M

Price/Earnings (Trailing)

-8.51

Price/Sales (Trailing)

24.75

EV/EBITDA

-2.11

Price/Free Cashflow

-12.04

XBIT Price/Sales (Trailing)

XBIT Profitability

EBT Margin

-287.99%

Return on Equity

-14.69%

Return on Assets

-13.49%

Free Cashflow Yield

-8.31%

XBIT Fundamentals

XBIT Revenue

Revenue (TTM)

10.6M

Rev. Growth (Yr)

-4.35%

Rev. Growth (Qtr)

2.11%

XBIT Earnings

Earnings (TTM)

-30.7M

Earnings Growth (Yr)

-162.11%

Earnings Growth (Qtr)

-115.79%

Breaking Down XBIT Revenue

52 Week Range

3.858.80

(Low)(High)

Last 7 days

-8.2%

Last 30 days

-9.0%

Last 90 days

48.1%

Trailing 12 Months

146.0%

How does XBIT drawdown profile look like?

XBIT Financial Health

Current Ratio

12.03

XBIT Investor Care

Shares Dilution (1Y)

0.06%

Diluted EPS (TTM)

-0.81

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	10.6M	0	0	0
2023	7.8M	0	8.8M	10.4M
2022	14.8M	11.1M	7.5M	3.8M
2021	36.2M	25.2M	19.2M	18.4M
2020	17.9M	26.6M	35.3M	44.0M
2019	414.5K	358.5K	508.5K	9.2M
2018	368.5K	361.5K	338.5K	400.5K
2017	125.1K	201.3K	277.4K	353.5K
2016	0	0	0	49.0K
2015	0	0	0	0
2014	0	0	0	0
2013	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of XBiotech Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 16, 2021	mckenzie w thorpe	sold (taxes)	-2,500,000	11.71	-213,493	-
Dec 16, 2021	mckenzie w thorpe	acquired	2,500,000	10.00	250,000	-
Oct 18, 2021	simard john	sold	-431,254	13.0683	-33,000	chief executive officer
Oct 15, 2021	simard john	sold	-226,471	13.3218	-17,000	chief executive officer
Oct 14, 2021	simard john	sold	-272,523	12.9005	-21,125	chief executive officer
Oct 13, 2021	simard john	sold	-139,526	12.83	-10,875	chief executive officer
Oct 12, 2021	simard john	sold	-229,939	12.7744	-18,000	chief executive officer
Oct 07, 2021	simard john	sold	-489,111	12.45	-39,286	chief executive officer
Oct 06, 2021	simard john	sold	-134,259	12.5312	-10,714	chief executive officer
Oct 05, 2021	simard john	sold	-180,058	12.6641	-14,218	chief executive officer

Which funds bought or sold XBIT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	new	-	211,006	211,006	0.06%
May 15, 2024	Man Group plc	sold off	-100	-233,420	-	-%
May 15, 2024	Cubist Systematic Strategies, LLC	new	-	42,715	42,715	-%
May 15, 2024	Tower Research Capital LLC (TRC)	added	2,048	8,873	9,081	-%
May 15, 2024	Brevan Howard Capital Management LP	new	-	167,299	167,299	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	reduced	-23.2	53,860	149,860	-%
May 15, 2024	MARSHALL WACE, LLP	new	-	444,540	444,540	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	added	16.54	4,356,600	7,539,500	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-57.91	-14,712	87,048	-%
May 15, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	added	3.27	635,583	1,213,960	0.03%

Are Funds Buying or Selling XBIT?

Are funds buying XBIT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own XBIT

No. of Funds

Unveiling XBiotech Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 07, 2024	simard john	19.9%	6,611,917	SC 13G/A
Feb 07, 2024	gut thomas	12.86%	3,914,111	SC 13G/A
Feb 07, 2024	mckenzie w thorpe	9.68%	-	SC 13G/A
Feb 10, 2023	simard john	-	-	SC 13G
Feb 10, 2023	gut thomas	12.86%	3,914,111	SC 13G
Feb 10, 2023	mckenzie w thorpe	9.87%	-	SC 13G
Jan 12, 2023	lombard international assurance s.a.	3.66%	1,114,256	SC 13G
Jun 16, 2022	gut thomas	12.88%	3,914,111	SC 13G
Feb 16, 2022	mckenzie w thorpe	9.81%	3,011,259	SC 13G
Feb 16, 2022	simard john	16.08%	5,093,547	SC 13G

Recent SEC filings of XBiotech Inc

View All Filings

Date Filed	Form Type	Document
May 10, 2024	10-Q	Quarterly Report
May 01, 2024	DEFA14A	DEFA14A
May 01, 2024	DEF 14A	DEF 14A
May 01, 2024	ARS	ARS
May 01, 2024	10-K/A	Annual Report
Apr 24, 2024	10-K/A	Annual Report
Mar 15, 2024	10-K	Annual Report
Feb 07, 2024	SC 13G/A	Major Ownership Report
Feb 07, 2024	SC 13G/A	Major Ownership Report
Feb 07, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to XBiotech Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.5B	6.8B	24.29%	3.18%	-8.29	7.22	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.16%	-22.78%	-56.17	9.31	75.20%	68.82%
BMRN	15.3B	2.5B	-12.17%	-12.66%	74.28	6.17	13.74%	186.89%
INCY	12.8B	3.8B	6.79%	-11.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	16.38%	112.85%	-10.26	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.64%	-52.21%	-12.19	9.71	394.93%	39.61%
AXSM	3.6B	251.0M	11.42%	-1.40%	-12.17	14.37	73.58%	-86.73%
ARWR	3.1B	240.7M	4.29%	-33.48%	-6.61	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-10.48%	-30.90%	-1.5K	3.07	56.43%	98.83%
SMALL-CAP
CPRX	2.0B	411.3M	8.25%	33.17%	30.22	4.78	60.38%	-34.49%
NVAX	1.8B	996.6M	212.62%	68.59%	-4.54	1.81	-26.66%	65.49%
CRBP	472.0M	881.7K	3.39%	323.08%	-13.98	481.06	-77.61%	33.36%
INO	339.4M	4.9M	19.20%	55.95%	-2.72	69.75	-54.97%	48.23%
IBIO	16.2M	2.1M	-2.59%	102.15%	-0.7	7.61	-13.45%	69.54%

XBiotech Inc News

Latest updates

XBiotech Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	2.1%	2,658,000	2,603,000	2,529,000	2,779,000	2,472,000	1,009,000	1,530,000	3,015,000	4,500,000	4,519,000	4,525,000	4,850,000	5,269,000	10,549,000	15,498,000	12,681,000	6,465,500	250,000	51,000	78,000	129,500
Gross Profit	-	-	-	-	-	284,000	1,465,000	1,323,000	287,000	3,454,000	3,409,000	3,165,000	2,546,000	3,021,500	1,123,000	2,297,000	3,007,000	-	-	-	-	-
Operating Expenses	26.4%	10,853,000	8,587,000	8,520,000	7,145,000	8,446,000	7,854,000	13,417,000	8,132,000	10,647,500	7,140,000	13,770,000	6,099,000	7,943,000	5,793,000	8,811,000	5,178,000	13,311,000	6,111,000	6,006,000	5,805,000	6,108,000
S&GA Expenses	-100.0%	-	782,500	973,000	915,000	1,128,500	840,000	3,023,000	1,314,000	1,866,000	1,541,000	4,516,000	1,465,000	4,482,000	3,447,000	6,246,000	4,023,000	2,974,000	1,578,000	1,313,000	1,278,000	1,265,000
R&D Expenses	25.9%	9,825,000	7,804,500	7,547,000	6,230,000	7,317,500	7,014,000	10,394,000	6,818,000	8,781,500	5,599,000	9,254,000	4,634,000	3,461,000	2,346,000	2,565,000	1,155,000	10,337,000	4,533,000	4,693,000	4,527,000	4,843,000
EBITDA Margin	-24.8%	-2.72	-2.18	-2.33	-3.68	-8.10	-4.80	-2.76	-1.77	-1.24	-0.91	-0.62	-	-	-	-	-	-	-	-	-	-
Income Taxes	125.4%	25,000	-98,500	308,000	-37,000	578,000	2,401,000	-2,608,000	-1,059,000	-1,200,500	-1,794,000	-4,573,000	-477,000	-254,000	-668,000	-332,000	-352,000	49,824,000	-	-	-	-
Earnings Before Taxes	-110.8%	-9,977,000	-4,733,500	-7,056,000	-3,853,000	-2,625,000	-10,257,000	-14,252,000	-6,454,000	-7,667,500	-5,055,000	-9,691,000	-3,045,000	-2,091,500	-3,194,000	-7,176,000	-366,000	736,319,000	-6,150,000	-5,852,000	-5,864,000	-
EBT Margin	-23.0%	-2.88	-2.34	-2.53	-3.98	-8.79	-5.17	-3.01	-1.96	-1.38	-1.04	-0.72	-	-	-	-	-	-	-	-	-	-
Net Income	-115.8%	-10,002,000	-4,635,000	-7,364,000	-3,816,000	-3,203,000	-12,658,000	-11,644,000	-5,395,000	-6,467,000	-3,261,000	-5,118,000	-2,568,000	-1,838,000	-2,526,000	-6,844,000	-14,000	686,495,000	-6,150,000	-5,852,000	-5,864,000	-6,111,000
Net Income Margin	-23.0%	-2.91	-2.37	-2.63	-4.02	-8.61	-4.84	-2.41	-1.37	-0.95	-0.67	-0.48	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-110.2%	-7,457,000	-3,548,000	-1,520,000	-4,814,000	-3,296,000	-1,360,000	-5,469,000	-5,284,000	-2,235,000	-4,102,000	71,085,000	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	0.5%	228	227	230	235	242	246	251	266	271	275	280	354	356	354	353	359	358	817	67.00	72.00	40.00
Current Assets	0.7%	203	202	204	210	216	220	223	239	243	247	250	325	328	326	252	258	258	716	41.00	46.00	13.00
Cash Equivalents	0.5%	201	200	202	143	153	157	161	226	232	237	239	315	240	237	238	230	242	715	40.00	45.00	12.00
Net PPE	-0.4%	25.00	25.00	25.00	26.00	26.00	26.00	27.00	27.00	28.00	28.00	29.00	28.00	28.00	27.00	26.00	25.00	25.00	25.00	26.00	26.00	27.00
Liabilities	139.1%	19.00	8.00	7.00	6.00	5.00	6.00	6.00	11.00	5.00	6.00	5.00	5.00	4.00	5.00	7.00	15.00	11.00	61.00	2.00	2.00	3.00
Current Liabilities	176.8%	17.00	6.00	5.00	4.00	4.00	4.00	4.00	8.00	3.00	3.00	4.00	4.00	3.00	4.00	6.00	14.00	10.00	60.00	2.00	2.00	3.00
Shareholder's Equity	-4.4%	209	219	223	229	237	240	245	256	266	269	274	349	352	349	346	344	347	756	65.00	69.00	37.00
Retained Earnings	-19.1%	-62.31	-52.31	-47.67	-40.31	-31.56	-27.75	-24.55	-11.89	-0.24	5.00	12.00	90.00	95.00	98.00	95.00	97.00	104	431	-255	-249	-243
Accumulated Depreciation	-100.0%	-	18.00	-	-	-	16.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Shares Outstanding	0.0%	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	30.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	140	-	-	-	133	-	-	-	428	-	-	-	294	-	582	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-109.8%	-7,202	-3,433	-1,487	-8,997	-4,808	-3,164	-1,150	-5,387	-5,123	-1,759	-3,402	72,797	1,809	-391	7,483	-11,568	-60,673	-3,746	-4,984	-4,863	-4,677
Share Based Compensation	-44.6%	381	688	955	914	705	1,038	1,128	1,448	1,448	1,354	1,133	1,040	936	2,794	3,156	3,175	3,456	1,505	797	486	570
Cashflow From Investing	-121.7%	-255	-115	61,826	-208	-6.00	-3,907	-59,742	-82.00	-161	-476	-700	-1,712	-637	-2,218	-694	-426	-389	674,994	-161	-31.00	-6.00
Cashflow From Financing	-	10,055	-	5.00	-14.00	-	-	-	-	-	33.00	-72,039	3,976	1,022	-150	2,230	278	-412,082	3,172	288	37,895	741
Dividend Payments	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

XBIT Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 9,825	$ 6,230
General and administrative	1,028	915
Total operating expenses	10,853	7,145
Loss from operations	(10,853)	(7,145)
Interest income	2,658	2,779
Other (expense) income	(200)	130
Foreign exchange (loss) gain	(1,582)	383
Total other income	876	3,292
Loss before income taxes	(9,977)	(3,853)
Income tax expense	(25)	(37)
Net loss	$ (10,002)	$ (3,816)
Net loss per share—basic and diluted (in dollars per share)	$ (0.33)	$ (0.13)
Shares used to compute basic and diluted net loss per share (in shares)	30,443,973	30,439,275

XBIT Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 201,039	$ 200,023
Accrued interest receivable	870	860
Income tax receivable	75	75
Prepaid expenses and other current assets	1,072	760
Total current assets	203,056	201,718
Property and equipment, net	24,802	24,897
Total assets	227,858	226,615
Current liabilities:
Accounts payable	2,607	2,516
Accrued expenses	4,194	3,501
Income tax payable	83	83
Convertible loan, related party	10,000	0
Total current liabilities	16,884	6,100
Long-term liabilities:
Income tax payable	1,694	1,669
Total liabilities	18,578	7,769
Shareholders’ equity:
Preferred stock, no par value, unlimited shares authorized, no shares outstanding	0	0
Common stock, no par value, unlimited shares authorized, 30,450,881 and 30,436,964 shares issued and outstanding at March 31, 2024 and December 31, 2023	271,588	271,152
Accumulated deficit	(62,308)	(52,306)
Total shareholders’ equity	209,280	218,846
Total liabilities and shareholders’ equity	$ 227,858	$ 226,615

About XBiotech Inc

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.

CEO	Mr. John Simard
WEBSITE	xbiotech.com
INDUSTRY	Biotechnology
EMPLOYEES	84

XBiotech Inc Frequently Asked Questions

What is the ticker symbol for XBiotech Inc? What does XBIT stand for in stocks?

XBIT is the stock ticker symbol of XBiotech Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of XBiotech Inc (XBIT)?

As of Wed May 15 2024, market cap of XBiotech Inc is 261.63 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of XBIT stock?

You can check XBIT's fair value in chart for subscribers.

What is the fair value of XBIT stock?

You can check XBIT's fair value in chart for subscribers. The fair value of XBiotech Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of XBiotech Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for XBIT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is XBiotech Inc a good stock to buy?

The fair value guage provides a quick view whether XBIT is over valued or under valued. Whether XBiotech Inc is cheap or expensive depends on the assumptions which impact XBiotech Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for XBIT.

What is XBiotech Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 15 2024, XBIT's PE ratio (Price to Earnings) is -8.51 and Price to Sales (PS) ratio is 24.75. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. XBIT PE ratio will change depending on the future growth rate expectations of investors.